Cytokinetics, IncorporatedSouth San Francisco, CA United States
Company Description
Cytokinetics studies the cytoskeleton to get to the heart of the problem. The biopharmaceutical firm's drug development technologies aim to treat disease by modulating muscle function through manipulation of the cytoskeleton (biological infrastructure of cells). Its pipeline includes lead candidate omecamtiv mecarbil, which is designed for the treatment of heart failure based on a cytoskeletal protein in the heart muscle. It is being developed in collaboration with
| 280 E. Grand Ave. | Phone: 650-624-3000 | http://www.cytokinetics.com |
| South San Francisco, CA 94080 | Fax: 650-624-3010 | 
Map This Company |
| United States |
Try a Full Premium Subscription
Access over 85 million companies
Call (866) 443-3939 or
Prepare for your Sales call
Try a Small Business Subscription
Starting $89 per month
Cytokinetics, Incorporated Rankings
Executives
| 20 executives listed for Cytokinetics, Incorporated's South San Francisco, CA location. | ||
| Chairman | L. Patrick Gage | |
|---|---|---|
| President, CEO, and Director | Robert Blum | |
| EVP Finance and CFO | SharonBarbari | |
Financials
| Company Type | Public - NASDAQ: CYTK Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 79 |
DNBiLeverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Cytokinetics, Incorporated now.
- Reduce risk.
- Drive greater profitability.
- Increase cash flow.
